JP Morgan raises target price on GSK
9th Feb 2026 12:41
(Sharecast News) - Analysts at JP Morgan raised their target price on drugmaker GSK to £22.50 on Monday on improving investor perception.
Read moreDirector dealings: GSK chairman raises stake
6th Feb 2026 15:00
(Sharecast News) - GSK revealed on Friday that non-executive chairman Jonathan Symonds had acquired 2,500 ordinary shres in the FTSE 100-listed drugmaker.
Read moreEU gives GSK's Nucala green light for use in uncontrolled COPD
6th Feb 2026 07:45
(Sharecast News) - Drugmaker GSK said on Friday that the European Commission has approved Nucala (mepolizumab) as an add‑on maintenance treatment for adults with uncontrolled COPD characterised by elevated blood eosinophils.
Read moreGSK sees slower sales growth in 2026 as patent loss looms
4th Feb 2026 07:19
(Sharecast News) - UK pharma giant GSK said turnover growth would slow this financial year as it looked to counter the expiry of an HIV drug patent and a deal with the Trump administration to lower product prices in the US.
Read moreGSK to cut up to 350 R&D jobs across UK, US
2nd Feb 2026 17:37
(Sharecast News) - GSK is planning to cut as many as 350 jobs in research & development in the UK and US, it was announced on Monday.
Read moreCiti starts AstraZeneca at 'buy', takes 'neutral' stance on GSK
27th Jan 2026 11:36
(Sharecast News) - Analysts at Citi initiated coverage of AstraZeneca and GSK on Tuesday, taking a bullish stance on the former but a more cautious view on the latter.
Read moreGSK vaccine given green light for all adults in Europe
26th Jan 2026 07:18
(Sharecast News) - The European Commission has approved GSK's respiratory syncytial virus (RSV) vaccine for use in all adults, the drugs giant announced on Monday.
Read moreGSK to snap up Rapt Therapeutics in $2.2bn deal
20th Jan 2026 07:57
(Sharecast News) - British drugs giant GSK has agreed to buy Rapt Therapeutics in a $2.2bn deal, it was announced on Tuesday, sending shares in the American allergy specialist soaring.
Read moreGSK chronic hepatitis B treatment hits goal in two studies
7th Jan 2026 07:36
(Sharecast News) - GSK on Wednesday said its potential chronic hepatitis B treatment had met primary endpoints in two trials that covered 1,800 patients from 29 countries.
Read moreJapan approves GSK treatment for severe asthma
6th Jan 2026 07:27
(Sharecast News) - GSK said Japan's Ministry of Health had approved its bronchial asthma treatment Exdensur after trial results showed "significant reductions" for patients with severe symptoms of the condition.
Read moreGSK's COPD treatment approved by Chinese regulators
5th Jan 2026 07:15
(Sharecast News) - Pharma giant GSK has received regulatory approval in China for its Nucala treatment for adults with inadequately controlled chronic obstructive pulmonary disease (COPD).
Read moreGSK asthma treatment approved by US regulators
17th Dec 2025 07:05
(Sharecast News) - US regulators have approved GSK's Exdensur treatment for severe asthma with an eosinophilic phenotype, marking the first ultra-long-acting biologic with twice-yearly dosing for this condition.
Read moreGSK secures MHRA nod for twice‑yearly respiratory treatment Exdensur
16th Dec 2025 07:53
(Sharecast News) - Drugmaker GSK said on Tuesday that Exdensur (depemokimab), an ultra-long-acting biologic to treat respiratory diseases, has received marketing authorisation from the UK's Medicines and Healthcare products Regulatory Agency.
Read moreGSK gets preliminary nod for two respiratory drugs in Europe
12th Dec 2025 13:57
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Read moreGSK's Arexy receives EU green light
12th Dec 2025 07:20
(Sharecast News) - GSK said on Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use had recommended expanding the use of Arexy, its RSV vaccine, to all adults aged 18 and over.
Read more